Inspire Medical Systems heads into its third-quarter report with an unusual setup: the company has already told investors that sales will shrink, yet the stock has rallied anyway. Management guided for revenue to fall 8% to 10% from a year ago, the steepest decline yet in a slide that went from 12% growth at the end of 2025 to a 7.6% drop last quarter. The question on November 2 is not whether the business contracts. It is whether the contraction looks like the trough of a reimbursement disruption or the start of something more durable.
Wall Street has anchored squarely to management's script. Consensus revenue of $204.3 million implies a 9% decline from $224.5 million a year ago, right at the midpoint of guidance and only modestly above the $200.6 million posted last quarter. Earnings are expected at $0.10 per share, down roughly 74% on negative sales leverage. The whisper number of $0.20 sits well above consensus, which suggests some investors expect cost discipline to show through even if revenue merely lands in line. For the full year, the Street's revenue estimate of about $844 million sits in the lower half of the $835 million to $875 million range, while the consensus EPS figure of $0.93 trails management's raised adjusted outlook of $1.05 to $1.45. That gap likely reflects some blending of restructuring charges into estimates, but it also means a clean adjusted quarter could make full-year forecasts look conservative.
The heart of the prior call was that the worst coding scenarios never arrived. Facility rates held steady under the new C codes, only two Medicare contractors require the payment-reducing modifier, and the cut there runs 0% to 30% rather than the feared 10% to 50%. Management also trimmed its estimate of the total coding and WISER prior-authorization headwind to $120 million to $130 million after the second-quarter hit came in at the low end of expectations. Validation this quarter would mean the headwind tracking at or below plan, no additional contractors adopting the modifier, and no sign that WISER is spreading beyond its six states. Any reversal on those fronts would undercut the argument that reimbursement clarity is improving faster than revenue.
The second test is Project Horizon, the plan to free roughly $30 million in annual spending for patient-flow initiatives such as prior-authorization support and post-implant engagement. It is too early for those programs to move revenue much, but the report should show whether restructuring charges of $20 million to $25 million are landing as forecast and whether consolidating to a single-source supply chain is proceeding without disruption. Early evidence that the Predictor screening study, which allows patient selection without a sleep endoscopy, is easing the referral funnel would also support the pivot from defense to growth. Updates on the revised Category 1 CPT application, which went back before the coding panel in September, and on the competitor preparing to launch will shape how investors frame 2027.
Sentiment has softened from distinctly bearish to merely skeptical, with the bearish reading easing to 48.7% from 60.2% a quarter ago. The stock has climbed 10.8% since the last report against a flat S&P 500, and its post-earnings range of $55.44 to $78.80 sits entirely above the prior quarter's $38.91 to $53.50 band. At $71.11, shares trade comfortably above the 200-day average near $59 but remain about 10% below their recent high, so this is a recovery trade rather than a breakout. That rally means some of the reimbursement relief is already priced in.
Ultimately, the report will be judged on whether Inspire can deliver a quarter that is bad by design but no worse than promised, while showing early signs that demand is stabilizing ahead of more favorable proposed 2027 facility rates. A revenue print at or above the midpoint, a coding headwind tracking within the narrowed range, and a reaffirmed or tightened full-year outlook would keep the bottoming narrative intact. A miss on the top line or a widening of the disruption estimate would suggest the recovery story arrived ahead of the evidence.